Masitinib: Phase II data

Researchers at the University of Lille Nord de France and colleagues reported data from a double-blind, French Phase II trial in 30 evaluable patients with progressive MS showing that once-daily 3-6 mg/kg oral masitinib non-significantly improved mean MSFC scores, the primary endpoint, from baseline to 12 months by 103% vs. a 60% reduction for placebo. Additionally, 32% of patients receiving masitinib (n=22) achieved a clinical response, defined as an increase in MSFC score relative to baseline of >100%, vs. 0% for placebo (n=8). Mean EDSS scores remained stable in both treatment groups. Masitinib was relatively well tolerated with asthenia, rash, nausea, edema and diarrhea reported as the most common adverse events. Data were published in BMC Neurology. ...